Due to January 18, a number of companies in the biomedical sector have issued performance forecasts. The data shows that the net profit of 4 companies has increased by more than 1000% year-on-year, namely Sansure Biotech , ZHEJIANG ORIENT GENE BIOTECH CO., LTD, Liferiver, and Wuhan Easy Diagnosis Biomedicine Co.,ltd.

After the outbreak of COVID-19, domestic companies accelerated the development of related products. Due to January 15, the number of COVID-19 detection reagents registered in China has reached 44, including 22 nucleic acid detection reagents. The performance of many listed companies has increased significantly due to the continuous increase in sales of COVID-19 detection products.

Sansure Biotech is the company with the largest expected performance increase. It is expected to realize the net profit attributable to the owners of the parent company from 2,556.26 million yuan to 2,806.26 million yuan in 2020, which will increase by 2,516.78 million yuan compared with the same period of the previous year (statutory disclosure data) Yuan to 2,766.78 million yuan, an increase of 6,375% to 7,008% year-on-year.

ZHEJIANG ORIENT GENE BIOTECH CO., LTD is expected to have a net profit of 1.556 billion yuan in 2020, a year-on-year increase of 1795.1%. After the outbreak of the COVID-19, ZHEJIANG ORIENT GENE BIOTECH CO., LTD quickly developed a variety of COVID-19 detection kits and a series of products such as influenza A and B influenza/coronavirus/respiratory syncytial virus/adenovirus antigen combined detection reagents, and coronavirus IgM/IgG antibody detection kits ( Both the colloidal gold method) and the rapid detection test paper for the coronavirus antigen (colloidal gold method) have achieved major sales breakthroughs, which will promote a substantial increase in overall business performance in 2020.

Liferiver expects a net profit of 0.88 billion yuan in 2020, an increase of 1608.47%. Liferiver is the first batch of companies to obtain the registration certificate for the COVID-19 nucleic acid test. The net profit in the first quarter of 2020 alone will reach 98.35 million yuan, a significant year-on-year increase. Liferiver frankly said that the increase in performance brought about by the COVID-19 is accidental and competition among peers is fierce. If the epidemic is effectively controlled globally, the sales of coronavirus nucleic acid testing related products will decline. In addition, with the popularization of vaccine products, the market demand for COVID-19 detection products will further decline.

Wuhan Easy Diagnosis Biomedicine Co.,ltd.'s net profit in 2020 is expected to be 0.44 billion to 0.5 billion yuan, a year-on-year increase of 959.58% -1104.07%. The coronavirus nucleic acid detection reagent products are shortlisted for centralized procurement and online procurement in many provinces and cities. During the reporting period, Wuhan Easy Diagnosis Biomedicine Co.,ltd.'s coronavirus nucleic acid reagents accounted for approximately 60% of total revenue.